UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

Recommendations

Info

Presentations Updated results: A phase I/IIa randomized trial of radium-223 + docetaxel versus docetaxel in patients with castration-resistant prostate cancer and bone metastases. Authors*: Michael J. Morris, Yohann Loriot, Christopher Sweeney, Karim Fizazi, Charles J. Ryan, Daniel H. Shevrin, Emmanuel S. Antonarakis, John Reeves, Kumari Chandrawansa, Martin Kornacker, Celestia S. Higano Abstract #: 5075 Presentation Date/Time: Saturday, June 4: 1:00 - 4:30 PM Location: Hall A, Poster Board #332 Session: Genitourinary (Prostate) Cancer Citation: J Clin Oncol 34, 2016 (suppl; abstr 5075) Ryan Research Interests: Dr. Ryan’s clinical practice focuses predominantly on advanced prostate cancer as well as germ cell (testicular) tumors and other malignancies of the genitourinary tract. His clinical and research work centers on the design and conduct of clinical trials of novel therapies for advanced prostate cancer, specifically secondary hormonal therapies targeting adrenal androgen signaling, androgen receptor targeted therapy and chemotherapy. In addition to clinical trials, Dr. Ryan collaborates with many laboratories researching the role of the androgen receptor and other signaling mechanisms in prostate cancer patients. http://cancer.ucsf.edu/people/profiles/ryan_charles.3649 *UCSF authors in bold 26
Presentations Immunogenicity of sipuleucel-T (Sip-T) in abiraterone (Abi)/ enzalutamide (Enz) sensitive and resistant metastatic castrateresistant prostate cancer (mCRPC). Authors*: Eric Jay Small, Lawrence Fong, David I. Quinn, Charles G. Drake, Dwayne Campogan, Tuyen Vu, Nadeem Anwar Sheikh, Nancy N. Chang, Daniel Peter Petrylak Abstract #: 5077 Presentation Date/Time: Saturday, June 4: 1:00 - 4:30 PM Location: Hall A, Poster Board # 334 Poster Session: Genitourinary (Prostate) Cancer Citation: J Clin Oncol 34, 2016 (suppl; abstr 5077) Small Research Interests: The Stand Up To Cancer Dream Team led by Dr. Eric Small is exploring the idea that resistance to hormonal therapy occurs as a result of the prostate cancer cells using common cellular responses - what the Dream Team calls “adaptive pathways” - to escape the current prostate cancer therapies. They believe that, by identifying these pathways and inhibiting them, they will be able to overcome treatment resistance and profoundly improve the care of men affected by this fatal disease. This team is a six institution consortium to include UC Los Angeles, UC Davis, UC Santa Cruz, University of British Columbia, Oregon Health and Sciences University, with UCSF as the lead administrative site. http://cancer.ucsf.edu/people/profiles/small_eric.3671 __________________________________________________________________________ Preliminary results for the advanced salivary gland carcinoma cohort of the phase 1b KEYNOTE-028 study of pembrolizumab. Authors*: Roger B. Cohen, Jean-Pierre Delord, Toshihiko Doi, Sarina Anne Piha-Paul, Stephen V. Liu, Jill Gilbert, Alain Patrick Algazi, Sara Cresta, Ruey-Long Hong, Christophe Le Tourneau, Daphne Day, Andrea Varga, Elena Elez, John M. Wallmark, Sanatan Saraf, Anne Morosky, Jonathan D. Cheng, Bhumsuk Keam Abstract #: 6017 Presentation Date/Time: Saturday, June 4: 1:00 - 4:30 PM Location: Hall A, Poster Board #339 Session: Head and Neck Cancer Citation: J Clin Oncol 34, 2016 (suppl; abstr 6017) *UCSF authors in bold 27
Page 1 and 2: UCSF HELEN DILLER FAMILY COMPREHENS
Page 3 and 4: HDFCCC Overview A Designated NCI Co
Page 5 and 6: HDFCCC Overview Core Capabilities S
Page 7 and 8: Presentations Presentations View fu
Page 9 and 10: Presentations Phase II trials of ce
Page 11 and 12: Presentations CRS-207 immunotherapy
Page 13 and 14: Presentations Long-term OS for pati
Page 15 and 16: Presentations Randomized phase 2 st
Page 17 and 18: Presentations Genomic Profiling to
Page 19 and 20: Presentations Validating RNAseq-sig
Page 21 and 22: Presentations Phase I/II study of V
Page 23 and 24: Presentations Clinical and genomic
Page 25: Presentations IMAAGEN trial safety
Page 29 and 30: Presentations Pembrolizumab for adv
Page 31 and 32: Presentations Novel T cell exhausti
Page 33 and 34: Presentations Correlation between m
Page 35 and 36: Presentations ATLAS: A randomized,
Page 37 and 38: Presentations A prospective analysi
Page 39 and 40: Presentations Circulating Biomarker
Page 41 and 42: Presentations Extended follow-up re
Page 43 and 44: Presentations Adjuvant temozolomide
Page 45 and 46: Presentations Ribociclib (LEE011) a
Page 47 and 48: Presentations Androgen receptor (AR
Page 49 and 50: Presentations Efficacy and hematolo
Page 51 and 52: Presentations IMpassion130: a Phase
Page 53 and 54: Presentations Randomized phase II t
Page 55 and 56: Presentations Phase II trial with t
Page 57 and 58: Presentations Academic and Communit
Page 59 and 60: Presentations Prevention of everoli
Page 61 and 62: Presentations A phase 2 randomized,
Page 63 and 64: Presentations PD-L1 expression, Can
Page 65 and 66: Presentations The Heart of the Matt
Page 67 and 68: Presentations 4-year results of the
Page 69 and 70: Presentations Impact of landmark re
Page 71 and 72: Presentations Phase II study of ali
Page 73 and 74: Presentations Can lay health worker
Page 75 and 76: Presentations Medical Management of
Page 77 and 78:
Presentations Prospective evaluatio
Page 79 and 80:
Presentations A phase II randomized
Page 81 and 82:
Presentations Early, molecular dete
Page 83 and 84:
Presentations Metastatic melanoma,
Page 85 and 86:
Presentations Three-year overall su
Page 87 and 88:
Presentations Heritage: A phase III
Page 89 and 90:
Presentations Determining barriers
Page 91 and 92:
Presentations Controversies in Loca
Page 93 and 94:
Presentations A pharmacodynamic stu
Page 95 and 96:
Presentations Final results of a ph
Page 97 and 98:
Presentations Comparative performan
Page 99 and 100:
Presentations Identification of sym
show all

UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

Create successful ePaper yourself

Delete template?

Save as template?